We believe that GSTP1 is able to reduce the risk of prostate cancer, which is expected to be a potential therapeutic target for prostate cancer, and also allows us to recognize the non-negligible role of GSH metabolism for prostate cancer. The gene discussed is GSTP1; the disease is prostate carcinoma.